21st Century Cell Culture for 21st Century Toxicology

被引:82
作者
Pamies, David [1 ]
Hartung, Thomas [1 ,2 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, CAAT, Baltimore, MD 21205 USA
[2] Univ Konstanz, CART Europe, D-78464 Constance, Germany
基金
美国国家卫生研究院;
关键词
ON-A-CHIP; ENDOTOXIN-INDUCIBLE CYTOTOXICITY; HUMAN BRAIN-DEVELOPMENT; IN-VITRO; MYCOPLASMA CONTAMINATION; PERFUSION APPARATUS; STEM-CELLS; TASK-FORCE; FOOD; THOUGHT;
D O I
10.1021/acs.chemrestox.6b00269
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
There is no good science in bad models. Cell culture is especially prone to artifacts. A number of novel cell culture technologies have become more broadly available in the 21st century, which allow overcoming limitations of traditional culture and are more physiologically relevant. These include the use of stem-cell derived human cells, cocultures of different cell types, scaffolds and extracellular matrices, perfusion platforms (such as microfluidics), 3D culture, organ-On-chip technologies, tissue architecture, and organ functionality. The physiological relevance of such models is fUrther enhanced by the measurement of biomarkers (e.g., key events of pathways), organ specific functionality, and more comprehensive assessment cell responses by high-content methods. These approaches are still rarely combined to create microphysiological sygtems. The complexity of the combination of these technologies can generate results closer to the in vivo situation but increases the number of parameters to control, bringing some new challenges. In fact, we do not argue that all cell culture needs to be that sophisticated. The efforts taken are determined by the purpose of our experiments and tests. If only a very specific molecular target to cell response is of interest, a very simple model, which reflects this, might be much more suited to allow standardization and high-throughput. However, the less defined the end point of interest and cellular response are, the better we should approximate organ- or tissue-like culture conditions to make physiological responses more probable. Besides these technologic advances, important progress in the quality assurance and reporting on cell cultures as well as the validation of cellular test systems brings the utility of cell cultures to a new level. The advancement and broader implementation of Good Cell Culture Practice (GCCP) is key here. In toxicology, this is a major prerequisite for meaningful and reliable results, ultimately supporting risk assessment and product development decisions.
引用
收藏
页码:43 / 52
页数:10
相关论文
共 80 条
  • [1] Adler S., 2007, REPORT RECOMMENDATIO
  • [2] Alepee N, 2014, ALTEX-ALTERN ANIM EX, V31, P441, DOI 10.14573/altex.1406111
  • [3] Developing Microphysiological Systems for Use as Regulatory Tools - Challenges and Opportunities
    Andersen, Melvin E.
    Betts, Kellyn
    Dragan, Yvonne
    Fitzpatrick, Suzanne
    Goodman, Jesse L.
    Hartung, Thomas
    Himmelfarb, Jonathan
    Ingber, Donald E.
    Jacobs, Abigail
    Kavlock, Robert
    Kolaja, Kyle
    Stevens, James L.
    Tagle, Dan
    Taylor, D. Lansing
    Throckmorton, Douglas
    [J]. ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION, 2014, 31 (03) : 364 - 367
  • [4] Consensus Guidance for Banking and Supply of Human Embryonic Stem Cell Lines for Research Purposes
    Andrews, Peter W.
    Arias-Diaz, Javard
    Auerbach, Jonathan
    Alvarez, Manuel
    Ahrlund-Richter, Lars
    Baker, Duncan
    Benvenisty, Nissim
    Ben-Josef, Dalit
    Blin, Guillaume
    Borghese, Lodovica
    Borstlap, Joeri
    Bruce, Kevin
    Bruestle, Oliver
    Buckle, Robin
    Camby, Carine
    Choo, Andre
    Chen, Wannhsin
    Collins, Daniel
    Colman, Alan
    Crombie, Catriona
    Crook, Jeremy
    Cypess, Ray
    De Sousa, Paul
    Dhawan, Jyotsna
    Douay, Luc
    Dvorak, Petr
    Dyke, Timothy
    Eriksson, Lena
    Firpo, Meri
    Fitzgerald, Claire
    Glover, Clive
    Gokhale, Paul
    Greene, Michele
    Ha, Hye-Yeong
    Hampl, Ales
    Healy, Lyn
    Hei, Derek
    Holm, Frida
    Hovatta, Outi
    Hunt, Charles
    Hwang, Shiaw-Min
    Inamdar, Maneesha
    Isasi, Rosario
    Itskovitz-Eldor, Joseph
    Jessie, Nancy
    Kim, Dong-Wook
    Kirzner, Rosemarie
    Kiatpongsan, Sorapop
    Knowles, Barbara
    Kuo, Hung-Chih
    [J]. STEM CELL REVIEWS AND REPORTS, 2009, 5 (04) : 301 - 314
  • [5] The scope of mycoplasma contamination within the biopharmaceutical industry
    Armstrong, Shayn E.
    Mariano, Jill A.
    Lundin, Daniel J.
    [J]. BIOLOGICALS, 2010, 38 (02) : 211 - 213
  • [6] Application of RPTEC/TERT1 cells for investigation of repeat dose nephrotoxicity: A transcriptomic study
    Aschauer, Lydia
    Limonciel, Alice
    Wilmes, Anja
    Stanzel, Sven
    Kopp-Schneider, Annette
    Hewitt, Philip
    Lukas, Arno
    Leonard, Martin O.
    Pfaller, Walter
    Jennings, Paul
    [J]. TOXICOLOGY IN VITRO, 2015, 30 (01) : 106 - 116
  • [7] Two Years Later: Journals Are Not Yet Enforcing the ARRIVE Guidelines on Reporting Standards for Pre-Clinical Animal Studies
    Baker, David
    Lidster, Katie
    Sottomayor, Ana
    Amor, Sandra
    [J]. PLOS BIOLOGY, 2014, 12 (01)
  • [8] Baker M, 2016, NATURE, V533, P452, DOI 10.1038/533452a
  • [9] Balls M, 2006, ALTEX S, V23, P270
  • [10] Bottini AA, 2009, ALTEX-ALTERN TIEREXP, V26, P3